

Lung Cancer Therapeutics: Global Markets

<https://marketpublishers.com/r/L535592BAABEN.html>

Date: November 2018

Pages: 161

Price: US\$ 1,375.00 (Single User License)

ID: L535592BAABEN

Abstracts

Report Scope:

This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.

Report Includes:

34 data tables and 32 additional tables

An in-depth overview of the global market for lung cancer therapeutics within the industry

Analyses of global market trends with data from 2017, estimates for 2018, and

projections of compound annual growth rates (CAGRs) through 2023

Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology

Assessment of major regulatory pathways and hurdles faced by lung cancer therapeutic product manufacturers

Information pertaining to lung cancer drug patent applications, expirations and the latest key technology developments, pipeline analysis, reimbursement scenarios, and unmet needs associated with the market

Dossier of mergers and acquisitions, new product development, strategies, research and development activities of major market players

Examination of competitive landscape for the lung cancer therapeutics market, and information pertaining to leading lung cancer market players, their marketed products, pipeline products and product patent expirations

Detailed company profiles of major manufacturers of oncology products, including Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Novartis International AG and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Introduction
Lung Cancer Types
In Situ Lung Cancer
Malignant Lung Tumors
Stages of Lung Cancer
Staging of NSCLC
Staging of SCLC
Risk Factors
Tobacco Smoking
Second-Hand Smoking (SHS)
Exposure to Asbestos
Exposure to Other Elements
Family History
Personal History
Lung Cancer Symptoms
Symptoms of Tumor Growth in the Lungs and Chest
Symptoms Caused by Metastases Beyond the Chest
Symptoms Caused by Tumor Secretion
Lung Cancer Diagnosis
General Screening Tests
Lung Cancer Management

Radiation Therapy
Chemotherapy
Surgery
Targeted Therapy for Lung Cancer
Immunotherapy for Lung Cancer
Palliative Treatment for Lung Cancer

CHAPTER 4 MARKET DYNAMICS

Market Drivers

Global Increase in Lung Cancer Incidence
Increase in Healthcare Expenditures and Government Funding in Key Countries
Robust Clinical Drug Pipeline
Increasing Life Expectancy of Lung Cancer Patients
Surge in Female Smokers

Market Restraints

Patent Expiration of Key Drug Molecules
Regulatory and Reimbursement Hurdles
Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies

Market Opportunities

Highest Incidence of Lung Cancer in Asia-Pacific
Increasing Demand for Targeted Therapies (EGFR or ALK Inhibitors, TKIs)
Increasing Incidence of NSCLC and its Non-responsiveness to Chemotherapy
Increasing Lung Cancer Incidence Among Non-Smokers
Clinical Trial Failures

CHAPTER 5 MARKET BREAKDOWN BY LUNG CANCER TYPE

Market Overview

Market Size and Forecast
Non-Small Cell Lung Cancer
Small Cell Lung Cancer

CHAPTER 6 MARKET BREAKDOWN BY REGION

Epidemiology of Lung Cancer
Global Market for Lung Cancer Therapeutics by Region
North America
Europe

Asia-Pacific
Middle East and Africa
South America

CHAPTER 7 REIMBURSEMENT LANDSCAPE

Introduction
United States
Lung Cancer Drug Reimbursement
Germany
Lung Cancer Drug Reimbursement
Brazil
China

CHAPTER 8 PATENT REVIEW

Patents Granted
Patent Expiration

CHAPTER 9 REGULATORY LANDSCAPE

Regulatory Challenges for Lung Cancer Therapeutics
North America
United States
Canada
Mexico
Europe
Mutual Recognition Procedure
Decentralized Procedure
Centralized Procedure
Asia-Pacific
Japan
China
India
South Korea
Middle East and Africa
Saudi Arabia
South Africa
South America

Brazil
Argentina

CHAPTER 10 COMPETITIVE LANDSCAPE

Major Lung Cancer Drug Companies
Eli Lilly and Co.
AstraZeneca Pharmaceuticals
Pfizer Inc.

CHAPTER 11 PIPELINE ANALYSIS

Introduction
Late-Stage Pipeline Drug Candidates
JAK Inhibitors for Lung Cancer
Third-Generation EGFR TKIs

CHAPTER 12 COMPANY PROFILES

ABBVIE INC.
Company Overview
Financials
Product Information
Development and Strategies
AMGEN INC.
Company Overview
ASTELLAS PHARMA INC.
Financials
ASTRAZENECA PLC
Company Overview
Financials
Products and Services
Developments and Strategies
BAYER AG
Company Overview
Financials
Product Information
BETA PHARMA INC.
Business Overview

Products and Services
BOEHRINGER INGELHEIM GMBH
Company Overview
Financials
Products and Services
Development and Strategies
BRISTOL-MYERS SQUIBB CO.
Company Overview
Financials
Products and Services
CELGENE CORP.
Company Overview
Financials
Products and Services
DAIICHI SANKYO CO., LTD.
Company Overview
Financials
Product and Services
ELI LILLY AND CO.
Company Overview
Financials
F. HOFFMANN-LA ROCHE AG
Company Overview
Financials
Products and Services
MERCK & CO., INC.
Company Overview
Financials
Products and Services
Development and Strategies
NOVARTIS INTERNATIONAL AG
Company Overview
Financials
Products and Services
Development and Strategies
PFIZER INC.
Company Overview
Financials
Product Information

Development and Strategies
TAKEDA PHARMACEUTICALS CO.
Company Overview

CHAPTER 13 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Lung Cancer Therapeutics, by Type, Through 2023

Table 1: TNM Classification of Malignant Tumors of Lung Cancer

Table 2: Five-Year Survival Rates, NSCLC and SCLC

Table 3: Targeted Therapy for Lung Cancer

Table 4: Targeted Antibodies Used in Lung Cancer

Table 5: Immunomodulators Used in Lung Cancer

Table 6: CAR T-Cell Therapy Clinical Trials Under Investigation

Table 7: Comparison of Overall Estimated Number of New Cancer Cases, by Type, 2018

Table 8: Age-Standardized Lung Cancer Incidence Rate, Rankings by Country, 2017

Table 9: Age-Standardized Lung Cancer Incidence Rate in Men, Rankings by Country, 2017

Table 10: Age-Standardized Lung Cancer Incidence Rate in Women, Ranking by Country, 2017

Table 11: Lung Cancer Incidence in Key Countries, 2017

Table 12: Proportion of Daily Cigarette Smokers in Europe, by Gender, 2014

Table 13: Patent Expiration of Lung Cancer Drugs

Table 14: Incidence of Lung Cancer in Asia-Pacific, 2016

Table 15: Prominent Drugs to Treat Lung Cancer

Table 16: Global Market for Lung Cancer Therapeutics, by Type, Through 2023

Table 17: Global Market for Lung Cancer Therapeutics, by Region, Through 2023

Table 18: Estimated Lung Cancer Statistics for Canada, 2017

Table 19: Lung Cancer Incidence in Canada, Male and Female

Table 20: Overall Healthcare Expenditures in Europe, by Country, Through 2015

Table 21: Number of New Lung Cancer Cases in the U.K., by Gender, 2015

Table 22: Medicare Part B: Lung Cancer Drug Payment Limits, 2018

Table 23: Lung Cancer Drug Reimbursement in Germany, 2018

Table 24: Oncology Drugs Covered by China's National Insurance

Table 25: U.S. Patents on Lung Cancer Therapeutics, 2001-2018

Table 26: Patent Expiration of Lung Cancer Drugs

Table 27: List of FDA-Approved Drugs, Through 2018

Table 28: Lung Cancer Drugs Approved by Health Canada, Through 2018

Table 29: NSCLC Drugs Authorized by the EMA, Through 2018

Table 30: NSCLC Drugs Pending Approval by the EMA, Through 2018

Table 31: NSCLC Drugs Withdrawn by the EMA, Through 2018

Table 32: NSCLC Drugs Pending Application Withdrawal by the EMA, Through 2018

Table 33: SCLC Drugs Pending Withdrawal by the EMA, Through 2018

Table 34: Global Ranking of Lung Cancer Drug Companies, 2017

Table 35: Eli Lilly and Co.: Lung Cancer Marketed Products and Investigational Molecules, Through 2018

Table 36: AstraZeneca Pharmaceuticals: Lung Cancer Marketed Products and Investigational Molecules, Through 2018

Table 37: Lung Cancer Pipeline Drugs, Through 2018

Table 38: Clinical Efficacy of Select Third-Generation EGFR TKIs in Clinical Development

Table 39: AbbVie Inc.: Net Revenue, 2015-2017

Table 40: AbbVie Inc.: Lung Cancer Pipeline

Table 41: Astellas Pharma Inc.: Net Revenue, 2013-2017

Table 42: Astellas Pharma Inc.: Net Revenue, by Country/Region, 2014-2017

Table 43: AstraZeneca Plc: Net Revenue, 2014-2017

Table 44: AstraZeneca Plc: Marketed Products, 2018

Table 45: Bayer AG: Net Revenue, 2015-2017

Table 46: Bayer AG: Lung Cancer Pipeline Molecules

Table 47: Boehringer Ingelheim GmbH: Net Revenue, 2014-2016

Table 48: Boehringer Ingelheim GmbH: Marketed Product, 2018

Table 49: Bristol-Myers Squibb: Net Revenue, 2014-2016

Table 50: Bristol-Myers Squibb: Marketed Products, 2018

Table 51: Celgene Corp.: Net Revenue, 2015-2016

Table 52: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2017

Table 53: Eli Lilly and Co.: Net Revenue, 2014-2017

Table 54: Eli Lilly and Co.: Net Revenue, by Segment, 2014-2016

Table 55: Eli Lilly and Co.: Net Revenue, by Oncology Drug, 2014-2016

Table 56: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017

Table 57: Tarceva: Drug Revenue, by Country/Region, 2016-2017

Table 58: Merck & Co., Inc.: Net Revenue, 2014-2016

Table 59: Novartis International AG: Net Revenue, by Segment, Through 2017

Table 60: Novartis International AG: Oncology Drugs Revenue, 2015-2017

Table 61: Pfizer Inc.: Net Revenue, 2014-2017

Table 62: Pfizer Inc.: Oncology Drug Revenue, 2015-2017

Table 63: Pfizer Inc.: Oncology Drugs Revenue, 2015-2017

Table 64: Pfizer Inc.: Lung Cancer Marketed Products and Investigational Drug Candidates, 2018

Table 65: Acronyms Used in Global Lung Cancer Therapeutics Market

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Lung Cancer Therapeutics, by Type, 2017-2023

Figure 1: Gross Anatomy of the Human Lung

Figure 2: Share of Lung Cancer Types, by Histology

Figure 3: National Cancer Institute Research Funding, 2011-2016

Figure 4: U.S. Smoking Statistics, by Gender, 2017

Figure 5: Percentage Share of Lung Cancer Incidence, by Type of Mutation

Figure 6: Global Market for Non-Small Cell Lung Cancer Therapeutics, 2017-2023

Figure 7: Global Market for Small Cell Lung Cancer Therapeutics, 2017-2023

Figure 8: Percentage Share of Global Lung Cancer Incidence, by Country/Region, 2018

Figure 9: North American Market for Lung Cancer Therapeutics, 2017-2023

Figure 10: Percentage Share of Estimated Cancer Incidence in North America, by Type, 2018

Figure 11: Percentage Share of Estimated Cancer Incidence in the United States, by Type, 2018

Figure 12: European Market for Lung Cancer Therapeutics, 2017-2023

Figure 13: Per Capita Spending on Market Sectors in Europe, 2015

Figure 14: Incidence Rates of Lung Cancer in the U.K., by Gender, 1993-2015

Figure 15: Incidence of Lung Cancer in Scotland, by Cancer Stage, 2014-2015

Figure 16: Incidence of Lung Cancer in Italy, by Gender, 2010 and 2015

Figure 17: Percentage Share of Estimated Cancer Incidence in France, by Type, 2018

Figure 18: Percentage Share of Estimated Cancer Incidence in Germany, by Type, 2018

Figure 19: Asia-Pacific Market for Lung Cancer Therapeutics, 2017-2023

Figure 20: Percentage Share of Estimated Cancer Incidence in Asia-Pacific, by Type, 2018

Figure 21: Estimated Cancer Incidence in Asia-Pacific, by Country, 2018

Figure 22: Middle East and African Market for Lung Cancer Therapeutics, 2017-2023

Figure 23: Percentage Share of Estimated Cancer Incidence in Africa, by Type, 2018

Figure 24: South American Market for Lung Cancer Therapeutics, 2017-2023

Figure 25: Percentage Share of Estimated Cancer Incidence in South America, by Type, 2018

Figure 26: Drug Reimbursement Scenerio in Germany

Figure 27: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada

Figure 28: Medical Device PMDA Approval Procedure

Figure 29: AbbVie Inc.: Revenue Share, by Region, 2016

- Figure 30: Erlotinib: Revenue, 2015-2016
- Figure 31: AstraZeneca Plc: Financial Performance, 2015-2017
- Figure 32: AstraZeneca Plc: Financial Performance, 2013-2017
- Figure 33: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
- Figure 34: AstraZeneca Plc: Revenue Share, by Country/Region, 2017
- Figure 35: Bayer AG: Revenue Share, by Region, 2017
- Figure 36: Bayer AG: Revenue Share, by Region, 2017
- Figure 37: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2016
- Figure 38: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2016
- Figure 39: Boehringer Ingelheim GmbH: Research and Development Expenditures, 2014-2016
- Figure 40: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2016
- Figure 41: Bristol-Myers Squibb: Revenue Share, by Business Segment, 2016
- Figure 42: Abraxane: Revenue, 2015-2017
- Figure 43: Daiichi Sankyo Co., Ltd.: Revenue Share, by Business Segment, 2016
- Figure 44: Eli Lilly and Co.: Revenue Share, by Country/Region, 2016
- Figure 45: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
- Figure 46: F. Hoffmann-La Roche Ltd.: Lung Cancer Drug Revenue, 2016-2017
- Figure 47: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
- Figure 48: Merck & Co., Inc.: Keytruda Revenue, 2015-2017
- Figure 49: Merck & Co., Inc.: Revenue Share, by Region, 2016
- Figure 50: Pfizer Inc.: Revenue Share, by Region, 2016
- Figure 51: Pfizer Inc.: Revenue Share, by Business Segment, 2016

I would like to order

Product name: Lung Cancer Therapeutics: Global Markets

Product link: <https://marketpublishers.com/r/L535592BAABEN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L535592BAABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970